Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Moodys
AstraZeneca
McKinsey
Mallinckrodt
Medtronic

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

CYMBALTA Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Cymbalta, and what generic alternatives are available?

Cymbalta is a drug marketed by Lilly and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has sixteen patent family members in fourteen countries.

The generic ingredient in CYMBALTA is duloxetine hydrochloride. There are forty-two drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the duloxetine hydrochloride profile page.

Drug patent expirations by year for CYMBALTA
Drug Prices for CYMBALTA

See drug prices for CYMBALTA

Drug Sales Revenue Trends for CYMBALTA

See drug sales revenues for CYMBALTA

Recent Clinical Trials for CYMBALTA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
PfizerPhase 4
Yuqi ChengEarly Phase 1
Otsuka Pharmaceutical Development & Commercialization, Inc.Phase 3

See all CYMBALTA clinical trials

Synonyms for CYMBALTA
(+)-(S)-N-Methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamin
(+)-(S)-N-Methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine monohydrochloride
(3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine
(3S)-N-methyl-3-(naphthalen-1-yloxy)-3-(2-thienyl)propan-1-amine
(3s)-N-Methyl-3-(Naphthalen-1-Yloxy)-3-(Thiophen-2-Yl)propan-1-Amine
(3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-yl-propan-1 amine
(3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-yl-propan-1-amine
(3s)-n-methyl-3-naphthalen-1-yloxy-3-thiophen-2-yl-propan-1amine
(3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine
(S)-(+)-N-methyl-3-(1-naphthaleneoxy)-3-(2-thienyl)propanamine
(S)-(+)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine
(S)-Duloxetine
(S)-Duloxetine;LY248686
(S)-N-methyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine
(S)-N-Methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine
(S)-N-Methyl-gamma-(1-naphthalenyloxy)-2-thiophenepropanamine
116539-59-4
2-Thiophenepropanamine, N-methyl-gamma-(1-naphthalenyloxy)-, (gammaS)-
2-Thiophenepropanamine, N-methyl-gamma-(1-naphthalenyloxy)-, (S)-
29E
539D594
AB00639911_15
AB00639911_16
AB00639911-13
AC-15704
AC1L1U0Q
AC1Q57H7
AJ-26827
AKOS015851058
AN-15424
ANW-63714
Ariclaim
AS-35259
AX8017669
BC209438
BDBM84745
C18H19NOS
CAS_136434-34-9
CCG-100763
CHEBI:36795
CHEMBL1175
CM14423
CPD000449282
CS-2885
CTK8B9954
D07880
DB00476
DTXSID6048385
duloxetine
Duloxetine (INN)
Duloxetine [INN:BAN]
Duloxetine Boehringer Ingelheim
duloxetine, (+)-isomer
FT-0657836
GTPL202
HMS2051I05
HSDB 7368
HY-B0161
J-003455
J-523680
KB-211921
LS-172322
LY 248686
LY-248686
LY248686
methyl[(3S)-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propyl]amine
MFCD06801358
MLS000758267
MLS001423946
MolPort-003-847-038
N-Methyl-gama-(1-naphthalenyloxy)-2-thiophenepropanamine
NC00013
NCGC00164559-01
NCGC00164559-02
NCGC00164559-04
O5TNM5N07U
PDSP1_000969
PDSP1_001385
PDSP2_000953
PDSP2_001369
RL00632
RTC-064103
SAM001247059
SB19317
SBI-0206832.P001
SC-19047
SCHEMBL8291
SMR000449282
UNII-O5TNM5N07U
VA11973
Xeristar
Yentreve
Yentreve (TN)
ZEUITGRIYCTCEM-KRWDZBQOSA-N
ZINC1536779

US Patents and Regulatory Information for CYMBALTA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly CYMBALTA duloxetine hydrochloride CAPSULE, DELAYED REL PELLETS;ORAL 021427-001 Aug 3, 2004 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Lilly CYMBALTA duloxetine hydrochloride CAPSULE, DELAYED REL PELLETS;ORAL 021427-002 Aug 3, 2004 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Lilly CYMBALTA duloxetine hydrochloride CAPSULE, DELAYED REL PELLETS;ORAL 021427-004 Aug 3, 2004 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CYMBALTA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly CYMBALTA duloxetine hydrochloride CAPSULE, DELAYED REL PELLETS;ORAL 021427-004 Aug 3, 2004   Start Trial   Start Trial
Lilly CYMBALTA duloxetine hydrochloride CAPSULE, DELAYED REL PELLETS;ORAL 021427-001 Aug 3, 2004   Start Trial   Start Trial
Lilly CYMBALTA duloxetine hydrochloride CAPSULE, DELAYED REL PELLETS;ORAL 021427-002 Aug 3, 2004   Start Trial   Start Trial
Lilly CYMBALTA duloxetine hydrochloride CAPSULE, DELAYED REL PELLETS;ORAL 021427-002 Aug 3, 2004   Start Trial   Start Trial
Lilly CYMBALTA duloxetine hydrochloride CAPSULE, DELAYED REL PELLETS;ORAL 021427-004 Aug 3, 2004   Start Trial   Start Trial
Lilly CYMBALTA duloxetine hydrochloride CAPSULE, DELAYED REL PELLETS;ORAL 021427-001 Aug 3, 2004   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for CYMBALTA
Drugname Dosage Strength RLD Date
➤ Subscribe Delayed-release Capsules 40 mg ➤ Subscribe   Start Trial
➤ Subscribe Delayed-release Capsules 20 mg, 30 mg and 60 mg ➤ Subscribe   Start Trial

Supplementary Protection Certificates for CYMBALTA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0273658 SPC/GB05/003 United Kingdom   Start Trial PRODUCT NAME: DULOXETINE AND PHARMACUETICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF, AND IN PARTICULAR DULOXETINE HYDROCHLORIDE; REGISTERED: UK EU/1/04/280/001 20040811; UK EU/1/04/280/002 20040811; UK EU/1/04/280/003 20040811; UK EU/1/04/280/004 20040811; UK EU/1/04/280/005 20040811; UK EU/1/04/280/006 20040811
0273658 C300171 Netherlands   Start Trial PRODUCT NAME: DULOXETINE EN FARMACEUTISCH AANVAARDBARE ZUURADDITIEZOUTEN DAARVAN, EN IN HET BIJZONDER DULOXETINE HYDROCHLORIDE; NATL REGISTRATION NO/DATE: EU/1/04/280/001-006 20040811
0273658 2005C/001 Belgium   Start Trial PRODUCT NAME: CHLORHYDRATE DE DULOXETINE; REGISTRATION NO/DATE: EU/1/04/280/001 20040811
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Moodys
Merck
McKesson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.